Primary hyperparathyroidism: an update

Habib, Zeina; Camacho, Pauline M.

doi:10.1097/med.0b013e32833f47e4

Cited by 14 publications

(9 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum calcium and phosphorus levels show no correlation with the clinical neuromuscular manifestations. Muscle biopsy reveals only varying degrees of atrophy without muscle fiber degeneration (Horak and Pourmand, 2000; Habib and Camacho, 2010). …”

Section: Step 1: Overview and Understanding Of Myopathies In Systemicmentioning

confidence: 99%

Stepwise Approach to Myopathy in Systemic Disease

Chawla¹

2011

Front. Neur.

View full text Add to dashboard Cite

Muscle diseases can constitute a large variety of both acquired and hereditary disorders. Myopathies in systemic disease results from several different disease processes including endocrine, inflammatory, paraneoplastic, infectious, drug- and toxin-induced, critical illness myopathy, metabolic, and myopathies with other systemic disorders. Patients with systemic myopathies often present acutely or sub acutely. On the other hand, familial myopathies or dystrophies generally present in a chronic fashion with exceptions of metabolic myopathies where symptoms on occasion can be precipitated acutely. Most of the inflammatory myopathies can have a chance association with malignant lesions; the incidence appears to be specifically increased only in patients with dermatomyositis. In dealing with myopathies associated with systemic illnesses, the focus will be on the acquired causes. Management is beyond the scope of this chapter. Prognosis is based upon the underlying cause and, most of the time, carries a good prognosis. In order to approach a patient with suspected myopathy from systemic disease, a stepwise approach is utilized.

show abstract

Section: Step 1: Overview and Understanding Of Myopathies In Systemicmentioning

confidence: 99%

Stepwise Approach to Myopathy in Systemic Disease

Chawla¹

2011

Front. Neur.

View full text Add to dashboard Cite

show abstract

“…But in 1925, Mandl was the first to remove a parathyroid tumor with significant improvement of the disease [1,2]. Primary Hyperparathyroidism (PHPT) affects at least 1 in 1000 persons and its incidence rises with age, with a peak in the seventh decade of life [3,4]. It is the third most common endocrine diagnosis [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…Primary Hyperparathyroidism (PHPT) affects at least 1 in 1000 persons and its incidence rises with age, with a peak in the seventh decade of life [3,4]. It is the third most common endocrine diagnosis [3,4]. The risk of developing PHPT is 5-fold greater in women compared to men after the age 75 years, while it is comparable between genders before the age of 45 years [5].…”

Section: Introductionmentioning

confidence: 99%

Increase Cancer Risk in Patients with Primary Hyperparathyroidism

Arrangoiz¹,

Sánchez-García²,

Moreno-Paquentin³

et al. 2019

AJOHNS

View full text Add to dashboard Cite

Introduction: Primary Hyperparathyroidism (PHPT) affects at least 1 in 1000 individuals and its incidence increases with age, with a peak incidence in the seventh decade of life. It is the third most common endocrine diagnosis. Several studies have identified a relationship between PHPT and an increased risk of developing malignancies such as breast, skin, colon, rectal, thyroid, prostate, and kidney cancers. The aim of this study was to report a cohort of patients with PHPT with concomitant cancer and compared them with PHPT without cancer. Methods:Retrospective study from a prospectively kept database of patients with PHPT treated by our group between January 2015 and July 2017. The operation performed by our group is, a minimally invasive radio-guided parathyroidectomy, which entails a bilateral neck exploration through a two-centimeter incision. The patients' characteristics were obtained and analyzed from the electronic medical records. Patients without complete medical records were not included in our study. All data were collected in a non-identifiable fashion in accordance with the principles outlined in the declaration of Helsinki and as required for our institutional review board approval. Results and Discussion:A total of 63 patients with PHPT were included in our study. Eighty percent of our patients were females; the mean age at diagnosis was 56.7 years (range: 29 years to 77 years). There were 23 patients with concomitant cancer (36.5% of the cases). The most frequently encountered malignancy was breast cancer in 14.3% of the cases (nine patients), thyroid cancer 7.9% (five patients), and skin cancer 6.3% (two patients with melanoma, one with basal-cell carcinoma and another one with squamous cell cancer). We did not identify a clinical or statistical difference between the two groups. The patients' demographics were very similar: gender (p=0.8), age (p=0.6), preoperative calcium levels (p=0.3), preoperative PTH levels (p=0.2), preoperative vitamin D levels (p=0.5) and preoperative urinary calcium levels (p=0.5). Conclusion:The available evidence at this time suggests a possible correlation between PHPT and malignancy. It remains to be clarified whether the risk is due to genetic predisposition to tumor development or a physiological associative effect. We recommend discussing with patients with a diagnosis of PHPT who are considering undergoing a parathyroidectomy about the possible increased risk of cancer seen in patients with PHPT. More studies are needed to determinate the exact relationship between the PHPT and the risk of developing cancer.

show abstract

“…1 Since that time the mnemonic ''stones, bones, abdominal groans, thrones, and psychiatric overtones'' were used to describe its manifestations. 2 Hyperparathyroidism classically produced osteitis fibrosa cystic and pathological fractures. However, this is not the common presentation of the disease nowadays.…”

mentioning

confidence: 99%

“…Furthermore, a newer entity of the disease is being identified, although its natural history is not fully understood, which is normocalcemic primary hyperparathyroidism. 2 Parathyroid hormone mediates its effect through cAMP as a second messenger. The hormone acts on PTH-1R receptor, which is present mainly on osteoblasts and in fewer amounts on osteoclasts.…”

mentioning

confidence: 99%